A Single Dose of a PD-1 Inhibitor Before Surgery May Predict Outcomes in Patients With Melanoma


“A single dose of a programmed cell death protein 1 (PD-1) inhibitor before resection for melanoma may predict clinical outcomes for patients. Researchers from the Abramson Cancer Center at the University of Pennsylvania—who documented this finding in the largest cohort of patients to be treated with anti–PD-1 drugs before surgery—also showed that immune responses brought on by this therapy can peak as early as 7 days after treatment—much earlier than previous studies have shown. These findings were published by Huang et al in Nature Medicine.”

Go to full article published by The ASCO Post on March 7, 2019.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.